This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If your require further information, please visit Terms of use page.
Sobi will discontinue the commercialisation of XIAPEX
This is to inform you that Sobi will discontinue the
commercialisation of XIAPEX for the treatment of Dupuytrens and
Peyronie’s disease by the end of 2019.
XIAPEX is a product owned by Endo Ventures Limited (‘Endo’).
Currently, XIAPEX is commercialised in the EU and other European and
Middle eastern countries by Sobi. Endo and Sobi have agreed to
terminate the cooperation agreement for Xiapex effective December
31, 2019. The decision to withdraw is based on commercial reasons
only and not for safety or efficacy concerns.
Endo & Sobi are committed to managing the de-registration of
Xiapex from the Sobi territories in an ethical and transparent
manner and Sobi will withdraw the EU Marketing Authorisation, which
will be effective from 1 March, 2020.
Please be assured that the wellbeing of patients during the
discontinuation process is of paramount importance to Sobi and we
are committed to the safety and comfort of all patients during the
process of transition to other therapies. We want to emphasize that,
subject to product availability from our supplier, Sobi is committed
to providing XIAPEX up until the end of 2019.
We would like to thank you for your interest in XIAPEX over the
years and deeply regret any inconvenience this may cause you.
If you have any questions or concerns, please do not hesitate to
contact us at your convenience.
After de-registration, we must refer any questions or requests for
Named Patient Use of Xiapex directly to Endo. Contact
www.endo.com/contact
